Navigation Links
Arena Submits Response to FDA Complete Response Letter for Lorcaserin
Date:1/3/2012

y and metabolic diseases.

Arena Pharmaceuticals® and Arena® are registered service marks of the company.

About Eisai Inc.Eisai Inc. was established in 1995 and is ranked among the top-25 US pharmaceutical companies (based on retail sales). The company began marketing its first product in the United States in 1997 and has rapidly grown to become a fully integrated pharmaceutical business. Eisai's areas of commercial focus include neurology, gastrointestinal disorders and oncology/critical care. The company serves as the US pharmaceutical operation of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world.

Eisai has a global product creation organization that includes US-based R&D facilities in Massachusetts, New Jersey, North Carolina and Pennsylvania as well as manufacturing facilities in Maryland and North Carolina. The company's areas of R&D focus include neuroscience; oncology; vascular, inflammatory and immunological reaction; and antibody-based programs. For more information about Eisai, please visit www.eisai.com/us.

Forward-Looking StatementsCertain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about the advancement, therapeutic indication and use, safety, efficacy, tolerability, mechanism of action, benefit-risk profile and potential of lorcaserin; the response to the CRL for the lorcaserin NDA, including its significance, confirmation of acceptance, assignment of a PDUFA date, the FDA's review and addressing issues raised in the CRL; the data and studies, analyses and other activities included in such response, including their significance and what they were intended to address, refine and assess; weight loss as an area of unmet need; the potential approval and commer
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Arena Pharmaceuticals to Present at the Oppenheimer 22nd Annual Healthcare Conference
2. Arena Pharmaceuticals to Present at the Piper Jaffray 23rd Annual Health Care Conference
3. Arena Pharmaceuticals Announces Third Quarter 2011 Financial Results
4. Arena Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference
5. Robert Hoffman to Rejoin Arena Pharmaceuticals as Vice President, Finance and Chief Financial Officer
6. Arena Pharmaceuticals Announces Second Quarter 2011 Financial Results
7. Arena and Eisai Announce Results of Re-Adjudication of Rat Mammary Tumors from Lorcaserin Carcinogenicity Study
8. Arena and Eisai Announce Completion of Study Measuring Lorcaserin Concentrations in Human Cerebrospinal Fluid and Related Analyses
9. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, August 9
10. Arena Pharmaceuticals Announces Phase 1 Results for APD811 for Pulmonary Arterial Hypertension
11. Meta-Analyses of Phase 3 Trials Show Obese and Overweight Patients Taking Arena Pharmaceuticals Lorcaserin Achieved Statistically Significant Weight Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 2014 Investor-Edge has initiated coverage ... FOLD ), Progenics Pharmaceuticals Inc. (NASDAQ: ... ), Idera Pharmaceuticals Inc. (NASDAQ: IDRA ), ... these five companies can be accessed at: http://investor-edge.com/register ... NASDAQ Composite ended at 4,419.48, up 2.40%, the Dow ...
(Date:10/22/2014)... , Oct. 22, 2014 Moms are ready ... trackers for themselves and their kids, according to the ... Health & Fitness Go Mobile for Moms, the latest ... BabyCenter, the number 1 pregnancy and parenting web and ... 55 percent of moms surveyed say they can,t think ...
(Date:10/22/2014)... 2014  CryoLife, Inc. (NYSE: CRY ), ... on cardiac and vascular surgery, announced today that ... Officer, has been elected to the Company,s Board of ... G. Anderson , Executive Chairman of CryoLife, stated, "Since joining ... an excellent leader who is well positioned to maximize ...
Breaking Medicine Technology:Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 2Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 3Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 4Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 5BabyCenter Finds Mom Ready to Live the "Measured Life" in its U.S. Mobile Mom 2014 Report: Health & Fitness Go Mobile for Moms 2BabyCenter Finds Mom Ready to Live the "Measured Life" in its U.S. Mobile Mom 2014 Report: Health & Fitness Go Mobile for Moms 3BabyCenter Finds Mom Ready to Live the "Measured Life" in its U.S. Mobile Mom 2014 Report: Health & Fitness Go Mobile for Moms 4Pat Mackin Joins CryoLife Board of Directors 2Pat Mackin Joins CryoLife Board of Directors 3
... Data presented yesterday showed that USL255, a novel ... less fluctuation in topiramate plasma levels than immediate-release ... These and other findings from the USL255 early ... the 64th annual American Epilepsy Society (AES) meeting ...
... Dec. 6, 2010 The Novartis Pharmaceutical Corporation ... disease control and tumor reduction in extensively pretreated ... become refractory after an autologous stem cell transplant, ... clinical trial presented today(1). In this ...
Cached Medicine Technology:Data Suggests Positive Pharmacokinetic Results From Phase I Research of Extended-Release Topiramate 2Data Suggests Positive Pharmacokinetic Results From Phase I Research of Extended-Release Topiramate 3Data Suggests Positive Pharmacokinetic Results From Phase I Research of Extended-Release Topiramate 4Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 2Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 3Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 4Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 5Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 6Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 7
(Date:10/22/2014)... 22, 2014 During the Western United ... supply runs dangerously low, Southern Oregon’s water is proving ... despite the lowest mountain snow pack on record in ... and early autumn.* That was the observation of journalist-hikers ... book “Hiking Southern Oregon,” during an interview with water ...
(Date:10/22/2014)... 22, 2014 Losing Weight Your Body’s Way ... staring you in the face, it certainly can be difficult ... your body an extra favor by doing it the healthy ... diets. Instead, listen to your body, exercise regularly, and choose ... essential to losing weight; you need to exercise more and ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Richard Carlson, ... an industry leader with over 25 years experience. ... leader in the areas related to EDI, B2B Commerce, ... is an Editorial Advisory Board member for Pharmaceutical Commerce ... Blue Fin Group is a management and technology ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, ... (IVF) are only about half as likely as white women ... research indicates, and the racial disparity persists even when donor ... of white patients became pregnant after IVF, compared to about ... IVF cycles over two years to tease out the impact ...
(Date:10/22/2014)... Maureen Salamon HealthDay Reporter ... crucial part of conventional in vitro fertilization (IVF) -- the ... take place in a device inside the vagina, new research ... that the device, called an INVOcell, might sharply cut costs ... make the technology more accessible to those who don,t live ...
Breaking Medicine News(10 mins):Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 2Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 4Health News:ReductionGuruMD Presents Ways to Improve Your Weight Loss Results 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4
... ... in the U.S., reNEW MAN (renewman.com) is promoting its national network of physicians to ... the company helps connect professional men that exhibit signs of low testosterone with a ... , ...
... , SATURDAY, Sept. 19 (HealthDay News) -- Taking a combination ... progestin, increases a woman,s risk for dying from lung cancer, ... an analysis of data from the Women,s Health Initiative trial ... United States who had been randomly assigned to take either ...
... ... extensive collection of lift chairs and other mobility products. , ... Raleigh, NC (PRWEB) September 19, 2009 -- Lift Chairs 101, a leader in ... lifts , offering a variety of styles and prices in order to better meet the mobility ...
... , LOS ANGELES, Sept. 18 Advocates for seniors ... response to statements he made in an LA Times story that ran ... , "As the Governor stepped in to stop eviction notices ... preparing to send out similar notices to an estimated 140,000 seniors and ...
... , MISSION VIEJO, Calif., Sept. 18 ... company of the Ensign(TM) group of skilled nursing, rehabilitative care services ... has declared a quarterly cash dividend of $0.045 per share of ... shareholders of record as of September 30, 2009. Ensign has been ...
... , , , , ... NxStage Medical, Inc. (Nasdaq: NXTM ), a leading manufacturer ... Wells, 57, has embarked on his third annual "Grandpa,s Road Trip" ... machine, the NxStage System One provides Mr. Wells the opportunity to ...
Cached Medicine News:Health News:Find a Local Andropause Doctor to Treat Low Testosterone with reNEW MAN 2Health News:Find a Local Andropause Doctor to Treat Low Testosterone with reNEW MAN 3Health News:Find a Local Andropause Doctor to Treat Low Testosterone with reNEW MAN 4Health News:Hormone Therapy May Make Lung Cancer More Likely 2Health News:Lift Chairs 101 Introduces New Bathtub Lift Line 2Health News:Disability Advocates Call-Out Governor Schwarzenegger for Honoring Mother-In-Law While Cutting Vital Services 2Health News:NxStage Patient Takes Dialysis Machine on Third Annual Patient Good-Will Tour 2Health News:NxStage Patient Takes Dialysis Machine on Third Annual Patient Good-Will Tour 3
Angled, 7.5 mm tying platforms.,Titanium, 111 mm long, 6 mm tying platforms....
Hatsis tying forceps, titanium, long thin tying platforms....
Gills Colibri forceps, very fine pointed tips....
Fine tying forceps, curved tips, wide handle....
Medicine Products: